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Abstract: Depression and anxiety occur at high rates among patients suffering an acute coronary 
syndrome (ACS). Both depressive symptoms and anxiety appear to adversely affect in-hospital 
and long term cardiac outcomes of post-ACS patients, independent of traditional risk factors. 
Despite their high prevalence and serious impact, mood and anxiety symptoms go unrecognized 
and untreated in most ACS patients and such symptoms (rather than being transient reactions 
to ACS) persist for months and beyond. The mechanisms by which depression and anxiety are 
linked to these negative medical outcomes are likely a combination of the effects of these con-
ditions on inflammation, catecholamines, heart rate variability, and endothelial function, along 
with effects on health-promoting behavior. Fortunately, standard treatments for these disorders 
appear to be safe, well-tolerated and efficacious in this population; indeed, selective serotonin 
reuptake inhibitors may actually improve cardiac outcomes. Future research goals include gaining 
a better understanding of the combined effects of depression and anxiety, as well as definitive 
prospective studies of the impact of treatment on cardiac outcomes. Clinically, protocols that 
allow for efficient and systematic screening, evaluation, and treatment for depression and anxiety 
in cardiac patients are critical to help patients avoid the devastating effects of these illnesses on 
quality of life and cardiac health.
Keywords: acute coronary syndrome, anxiety, anxiety disorders, depression, myocardial 
infarction, unstable angina
Introduction
Depression and anxiety are common among patients who have an acute coronary 
syndrome (ACS) or other major cardiovascular event. Despite their frequency, these 
psychiatric syndromes often go unrecognized and can persist for months to years, 
  substantially impacting quality of life.1–4 Furthermore, both depression and anxiety 
have been independently associated with negative cardiac outcomes in patients with 
acute cardiac events and, indeed, across the spectrum of cardiac disease.5–8 Fortunately, 
safe and effective treatments exist for depression and anxiety disorders in these 
patients,9–11 and systematic evaluation of cardiac patients for psychiatric symptoms 
has the potential to substantially improve outcomes.12
In this review, we will examine the phenomenology of ACS and outline the prevalence 
and medical impact of depression and anxiety in patients with ACS and other forms 
of cardiovascular illness. We will discuss the mechanisms by which mood and anxiety 
symptoms may impair cardiac prognosis and will describe treatment considerations 
in this population. In the literature, depression in cardiac patients has been defined in 
several different ways, with some studies focusing on the formal syndrome of major Neuropsychiatric Disease and Treatment 2010:6 124
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depression and others focusing on elevated depressive symp-
toms on self-report measures. Similarly, though most studies 
of anxiety in heart disease have used self-report measures, 
there is increasing study of specific anxiety disorders among 
patients with cardiac illness. In this article, we will review 
the literature on both self-reported symptoms of depression 
and anxiety and the existing data on specific depressive and 
anxiety disorders.
Acute coronary syndromes:  
an overview
Cardiovascular disease is the number one cause of death in the 
world.13 Among patients with cardiovascular disease, unstable 
angina (UA) and myocardial infarction (MI) are severe, 
life-threatening conditions that represent sudden myocardial 
ischemia (loss of blood flow to the heart muscle, with loss 
of oxygen to cardiac cells). Both UA and MI are generally 
captured under the umbrella term ACS; this term represents 
a wide clinical spectrum of myocardial ischemia severity, 
ranging from UA (by definition, ischemia without myocar-
dial injury) to MI, representing ischemia with resultant cell 
death (Figure 1).
Each year, more than one million Americans suffer an 
ACS.14 Risk factors for having cardiac disease, and ultimately 
an ACS, include gender (men are slightly more likely to 
have cardiac illness), age (men over 45 years and women 
over 55 years), family history of cardiovascular disease, and 
  modifiable risk factors.14 ACS is more common in men (eg, 
58% of all ACS events occurred in men in 2005), though ACS 
prevalence in women approaches that of men in older age.14 
Modifiable risk factors for an ACS include hypertension, 
hyperlipidemia, diabetes, sedentary lifestyle, and smoking. 
In addition to these risk factors, it has become increasingly 
clear that psychological factors, particularly depression and 
anxiety, may play an important and independent role in the 
development and propagation of cardiac disease. Further, 
some have begun to suggest that depression, in particular, 
be included among the list of classic cardiac risk factors 
given the strength of evidence linking this illness to cardiac 
outcomes.15,16
Pathophysiologically, the most common cause for an ACS 
is the disruption of a previously nonsevere atherosclerotic 
plaque. Indeed, it is now recognized that the great majority 
of coronary atherosclerotic plaques that lead to ACS are 
typically relatively nonobstructive prior to the ACS, with 
a predisposition to rupture that is determined more by their 
intrinsic biology, than degree of protrusion into the coronary 
lumen.17
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Figure 1 Pathophysiology of acute coronary syndrome.
Abbreviation: CPK-MB, creatine phosphokinase-MB fraction.Neuropsychiatric Disease and Treatment 2010:6 125
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The characteristic “vulnerable” atherosclerotic plaque is 
one that has a rich lipid core (typically filled with necrotic, 
highly inflammatory debris), a large number of inflammatory 
cells (such as macrophages), a paucity of fibroblasts, and a 
relatively thin fibrous cap separating the plaque contents 
from the blood.17 In the context of a trigger, biological or 
physiological, the thin fibrous cap may rupture, leading to 
a cascade of events ranging from an asymptomatic cardiac 
event to sudden cardiac death.
In the context of plaque rupture, a series of inflammatory 
and platelet-related events lead to the formation of a 
  thrombus, a blood clot, on the surface of the plaque, which 
may lead to occlusion of the coronary artery.18 Factors that 
determine this process include both the size and severity 
of the plaque rupture, as well as the vigor of the biological 
response to plaque rupture, including severity of platelet 
response and coagulation activation.
If the coronary thrombosis is significant enough, blood 
flow to that area of the heart is either reduced or blocked 
and myocardial ischemia results. Moreover, a substantial 
degree of myocardial ischemia in the context of ACS is not 
only due to occlusion of the epicardial coronary vessel, but 
also to downstream embolization of platelet-rich debris to 
the resistance microvasculature.19 In the setting of acute 
  myocardial ischemia, classic signs and symptoms in men that 
may follow include chest heaviness that may radiate to the jaw 
or arm, diaphoresis, shortness of breath, and lightheadedness. 
Such symptoms may be less common in certain important 
populations, such as women and the elderly.
Diagnostically, patients with suspected ACS are evaluated 
with 12-lead electrocardiography (ECG). Diagnostic changes 
on ECG include depression or elevation of the ST-segments; 
the presence of either of these findings identifies a patient 
with severe coronary ischemia (ST-depression) or frank 
  myocardial injury (ST-elevation). If the ACS leads to 
  cardiac cell death, typically detected using sensitive tests for 
  myocardial cell death (eg, serum troponin) then, by definition, 
it is an MI. In addition to being useful for diagnosis of MI, 
serum troponins also predict the risk for recurrent MI, as well 
as death.20 Accordingly, troponin elevation in the setting of 
an ACS identifies a population of patients that are typically 
managed in a more aggressive fashion clinically.
Typical acute treatments for ACS include oxygen, 
aspirin, beta-adrenergic blocking agents, high dose 
lipid-lowering agents, anticoagulants such as heparin, as 
well as nitroglycerin, and/or morphine sulfate for ongoing 
  symptoms. More aggressive antithrombotic drugs such 
as clopidogrel (an oral antiplatelet agent) and/or platelet 
  glycoprotein antagonists are widely used in this setting 
as well.
Goals of acute treatment are to eradicate symp-
toms, normalize electrocardiogram findings, and prevent 
  complications. In addition to medication treatment, patients 
(especially those suffering a myocardial infarction with ST-seg-
ment elevation seen on the ECG) will undergo reperfusion 
treatment. Most commonly, the patient will undergo urgent/
emergent cardiac catheterization with coronary angiography, 
to identify areas of stenosis within the coronary artery sys-
tem. These narrowed areas may then be dilated using balloon 
angioplasty, most commonly with adjunctive placement of 
a coronary stent. In the absence of available catheterization 
facilities, reperfusion can also be achieved using fibrinolytic 
agents, medications that may dissolve the intracoronary throm-
bosis, although the success of fibrinolysis is significantly lower 
than angioplasty and stenting.21
Once the symptoms of ACS have acutely subsided, 
  important medication interventions to reduce risk of future 
complications and recurrence include the use of a wide array of 
medications, including beta-blockers, angiotensin-converting 
enzyme inhibitors, cholesterol-lowering agents, and 
antiplatelet agents (aspirin, clopidogrel). Lifestyle and risk 
factor modification is also essential.
Depression and anxiety in patients 
with acute cardiac disease
Among patients with cardiac disease, depression is com-
mon, persistent, and under recognized. The syndrome of 
major depression (Table 1) is present in approximately 15% 
of patients with cardiac disease,22 including those suffering 
ACS.23,24 Such a rate is substantially higher than that seen in 
the general population (4% to 5%)25 or primary care patients 
(8% to 10%).26 Though some cardiac illnesses may have 
associated impairments of appetite, concentration, sleep, and 
energy, true depression (with persistent depressed mood or 
anhedonia) is not a normal consequence of cardiac disease.
Rather than being a transient reaction to having 
  cardiac disease, depression in cardiac patients is often 
both chronic and recurrent.27,28 For example, the large 
Sertraline Antidepressant Heart Attack Randomized Trial 
(SADHART) trial27 found that, among ACS patients who 
entered the hospital with major depression, 94% of such 
patients had been depressed for over one month, 61% had 
been depressed for over six months and more than half had 
a prior major depressive episode. Furthermore, depressive 
symptoms are not transient after myocardial infarction, but 
instead persist if untreated. Two studies have found that Neuropsychiatric Disease and Treatment 2010:6 126
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depressive symptoms are essentially stable over the year 
following MI, with little reduction of symptoms over this 
period in untreated patients.3,29 Despite the frequency and 
persistence of depression in this cohort, it often goes unrec-
ognized and untreated in the vast majority of patients suf-
fering ACS. A pair of studies on acute cardiac units found 
that front-line clinicians were unable to identify depression 
in their post-MI patients,2,4 and rates of depression treat-
ment in this setting have been less than 15%.30,31
Anxiety is also common among patients with acute 
  cardiovascular disease. Elevated levels of self-reported 
  anxiety are present in 20% to 50% of patients following 
acute MI,1,32–34 with up to one quarter experiencing symptoms 
of anxiety at least as intense as the average inpatient on a 
  psychiatric unit.35 Anxiety often persists after such car-
diac events and, among patients with anxiety shortly after 
ACS, many have clinically significant anxiety up to 2 years 
later.1,36,37 The finding that patients with stable coronary 
heart disease have higher levels of anxiety than the general 
population, with prevalence rates ranging from 16% to 42%, 
is further evidence of the pervasive nature of anxiety in 
coronary heart disease patients.6,38–40
In addition to elevated levels of overall anxiety as measured 
on anxiety scales, formal anxiety disorders are more common 
in cardiac patients than in the general population. One 
cross-sectional study utilizing semi-structured diagnostic 
  interviews found that 36% of patients met criteria for an anxiety 
disorder at the time of evaluation and 45% had a lifetime 
  history of an anxiety disorder.41 Generalized anxiety disorder 
is present in up to 24% of patients with cardiac disease,6,41,42 
and panic disorder also occurs at substantially elevated rates 
among patients with cardiovascular disease, with 5% to 50% 
of cardiac patients having active panic disorder.41,43–45
As with depression, clinically significant anxiety in 
post-ACS patients often goes unrecognized and untreated 
by front-line clinicians on cardiac inpatient units.2 Follow-up 
of patients with these symptoms is equally limited; in one 
study, roughly one third of patients who had elevated anxiety 
following an ACS were questioned about these symptoms 
by their medical clinicians over the next year.1
Links between depression, anxiety, 
and negative cardiac outcomes 
among patients suffering acute 
ischemic events
There is substantial evidence to suggest that depression is 
independently associated with negative cardiac outcomes 
across the spectrum of cardiac disease. Depression in healthy 
persons without cardiac disease has been associated with 
the development of coronary artery disease. The Johns 
Hopkins Precursor study followed male medical students for 
40 years and found depression to independently predict the 
  subsequent development of cardiac disease and MI.46 Since 
that time, there have been numerous studies of healthy men 
and women linking depression to the onset of cardiac illness; 
a meta-analysis of this population found that depression was 
associated with a 60% increase in cardiac disease.47
Among patients with existing cardiac disease, depression 
has been associated with progression of the illness. Patients 
found to have depression when diagnosed with coronary 
artery disease at cardiac catheterization are more likely to 
have acute cardiovascular/ischemic events than nondepressed 
patients48 and hypertensive patients with depression more 
likely to die of their cardiac disease.49
Finally, and most strikingly, patients with depression 
in the setting of acute myocardial ischemia (ACS) have 
  substantially impaired medical/cardiac outcomes compared 
to those without depression. Specifically, post-MI depression 
is associated with poor health-related quality of life, recurrent 
Table 1 Criteria for a major depressive episode
A.   Five (or more) of the following symptoms have been present most  
of the day, nearly every day, during the same two-week period; at least 
one of the symptoms is either depressed mood or loss of interest  
or pleasure:
  1) depressed mood
  2)   markedly diminished interest or pleasure in all, or almost all, 
  activities
  3)   decrease or increase in appetite, or significant weight loss when not 
dieting or weight gain (eg, a change of more than 5% of body weight 
in a month)
  4) insomnia or hypersomnia
  5)   psychomotor agitation or retardation (observable by others, not 
merely subjective feelings of restlessness or being slowed down)
  6) fatigue or loss of energy
  7)   feelings of worthlessness or excessive or inappropriate guilt (not 
merely self-reproach or guilt about being sick)
  8) diminished ability to think or concentrate, or indecisiveness
  9) recurrent thoughts of death or suicidal ideation
B.      The symptoms cause clinically significant distress or impairment in 
social, occupational, or other important areas of functioning.
C.   The symptoms are not due to the direct physiological effects of 
a substance (eg, a drug of abuse, a medication), a general medical 
condition (eg, hypothyroidism), and are not better accounted for  
by bereavement.
Note: Adapted with permission from American Psychiatric Association. Diagnostic and 
Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric 
Press, 1994.Neuropsychiatric Disease and Treatment 2010:6 127
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cardiac events, and mortality, independent of other medical 
and demographic characteristics.24,50,51 These links appear to 
exist either when depression is measured by self-report or 
by a structured clinical interview.5 A 2004 meta-analysis of 
22 studies that included over 6000 patients found that the 
uncorrected relative risks of recurrent cardiac events and 
cardiac mortality in the year following MI were 2.0 and 2.6 
in patients with depression in the post-MI period compared 
to those without depression.24
Depressive symptoms in the post-ACS period can have far 
reaching consequences. A recent longitudinal study of post-
ACS depression found that baseline depression severity a few 
weeks after ACS was a strong and independent risk factor for 
cardiac mortality approximately 7 years after the index event.52 
Findings from this study and others indicate that ACS patients 
whose depression is resistant to standard treatments appear to 
be at highest risk of suffering adverse cardiac outcomes.52–54 
It is unclear whether this is because the depression persists or 
whether this is a separate subtype of depression.
In addition to the long term effects of post-ACS depression, 
it appears that depression may also have immediate 
  detrimental effects among those admitted to the hospital with 
acute myocardial ischemia. In this regard, at least two studies 
have found that MI patients who enter the hospital with an 
ongoing major depressive episode are more likely to have an 
in-hospital cardiac complication.31,55 Though most studies of 
ACS patients have primarily evaluated depression after MI, 
depression in the setting of UA has also been specifically 
associated with cardiac morbidity and mortality.23
Anxiety also appears to be linked to negative cardiac 
  outcomes across the spectrum of cardiac disease. Persons with 
elevated anxiety have higher rates of subsequent development 
of coronary heart disease than nonanxious persons, independent 
of other risk factors. Indeed, anxiety may be more strongly 
associated with the onset of cardiac disease than depression.8 
In particular, worry is a component of anxiety that appears 
to be especially associated with cardiac disease.56,57 Among 
patients with acute cardiovascular disease, the population 
of patients most vulnerable to catastrophic cardiac events 
and complications, several studies have found that elevated 
anxiety after MI has been independently associated with in-
hospital cardiac complications.58–60 Furthermore, though prior 
studies found no such association,34,61 multiple recent studies 
have also found that anxiety following MI is associated with 
longer-term cardiac complications and mortality.1,6,62 These 
studies include a recent well-designed study by Frasure-Smith 
and colleagues6 finding that generalized anxiety disorder 
(GAD) in the setting of coronary artery disease was associated 
with 2 year major adverse cardiac events, independent of other 
patient characteristics and a study by Strik and coworkers62 
finding that post-MI anxiety symptoms, independent of 
depression and medical characteristics, predicted recurrent 
cardiac events.
Do depression and anxiety have additive effects on 
cardiovascular outcomes among patients with myocardial 
ischemic events? There has been a relative paucity of stud-
ies in this area and thus far the results have been mixed. 
A recent analysis of data from the Women’s Ischemia 
Syndrome Evaluation (WISE) study found that depressed 
women with higher levels of anxiety were more likely to 
have adverse cardiovascular events than depressed women 
with low anxiety.63 In contrast, the previously mentioned 
study by Frasure-Smith and colleagues6 found that both major 
  depression and generalized anxiety disorder were associated 
with cardiac events, but that patients with both disorders were 
not at further elevated risk.
In sum, depression and anxiety appear to be independently 
associated with adverse cardiovascular outcomes among 
patients with ischemic heart disease; depression, in particular, 
appears to be clearly associated with cardiac events in both 
the short and long term.
Potential mechanisms linking 
depression/anxiety and  
myocardial ischemia
Given the substantial literature linking depression and anxiety 
with adverse cardiac events, there has been an increasing focus 
on determining the mechanisms by which these links may occur 
(Figure 2). Overall, there are two mechanistic categories that 
likely contribute to these associations: physiologic effects and 
behavioral effects. We will first discuss physiologic effects.
Platelet activity and aggregation
Platelet activity and aggregation are key components of 
acute myocardial ischemia and evidence of increased 
  platelet activity and aggregation has been found in patients 
with depression.64–66 The connection between depression 
and platelet hyper-reactivity (and subsequent aggregation) 
may be mediated by serotonin. Serotonin is found both 
in the whole blood and in platelets and plays an essential 
role in platelet activation. When serotonin binds to 
5-hydroxytryptamine-2 (5HT-2) receptors on platelets, 
it causes the release of procoagulant factors stored in the 
platelets and enhances platelet aggregation, leading to clot 
formation. In normal coronary arteries, thrombus formation 
and ischemia are prevented by serotonin’s stimulation of Neuropsychiatric Disease and Treatment 2010:6 128
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the endothelium to release nitric oxide, which results in 
  vasodilation in the area surrounding the clot. In atherosclerotic 
arteries, however, damage to the endothelium prevents the 
release of nitric oxide with the result that serotonin leads to 
vasoconstriction.67 Given this, it is not surprising that elevated 
serotonin blood levels have been associated with coronary 
artery disease and cardiac events.68
The serotonergic system has also been implicated in the 
pathogenesis of major depression. Although evidence is 
not conclusive, several researchers have found that patients 
with depression (with and without heart disease) have 
  abnormalities in whole blood and platelet serotonin levels,69,70 
increased platelet serotonin receptor concentrations,71,72 and 
abnormally low platelet serotonin transporter levels,73 all of 
which could lead to serotonin-linked platelet dysfunction and 
could provide a explanation for how depression could lead 
to adverse cardiovascular outcomes.
Less is known about the effects of anxiety on platelet 
aggregation and activity, but the available evidence suggests 
that serotonin may also mediate changes in platelets in 
  anxious patients. Abnormalities in the serotonergic system 
have been implicated in the pathogenesis of anxiety disorders 
and patients with phobic anxiety have been found to have 
  abnormalities in the coagulation and fibrinolytic system leading 
to a hypercoagulable state.74 Furthermore, abnormalities in 
serotonin blood levels,75 platelet serotonin transporters,76 and 
platelet intracellular calcium levels in response to stimula-
tion77 (increasing sensitivity to procoagulant factors) have 
been reported in patients with specific anxiety disorders. 
In addition to these mechanisms, acute stress has also been 
associated with platelet hyperactivity, increased blood 
  viscosity, and hemoconcentration,78,79 potentially increasing 
the risk for thrombosis and other cardiovascular complica-
tions mediated through platelet hyperactivity and increased 
blood viscosity.
Inflammation
Inflammation appears to play a key role in the pathogenesis of 
acute ischemic events. Inflammatory cytokines such as tumor 
necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) are 
actively involved in the pathogenesis of atherosclerosis,80,81 
and elevations of inflammatory markers, especially C-reactive 
protein (CRP), are independently associated with mortality 
following ACS.80,82 Depression is similarly associated with 
elevations of other inflammatory markers (eg, IL-1, IL-6, 
and TNF-α),83 and this proinflammatory state in depression 
may lead to development or propagation of myocardial 
ischemic events.
Impaired health- 
promoting 
behavior
Adverse 
physiologic effects 
Reduced 
adherence to:
• Low fat diet 
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• Smoking 
cessation
• Medication
Low cardiac rehab 
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Figure 2 Putative mechanisms linking depression/anxiety and cardiac outcomes in acute coronary syndrome (ACS) patients.Neuropsychiatric Disease and Treatment 2010:6 129
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As with platelet activation, there is less data on the links 
between anxiety and inflammation, but levels of circulating 
inflammatory markers are abnormal in persons with elevated 
anxiety. A large study of healthy adults found elevated levels 
of anxiety to be independently associated with abnormalities 
of multiple inflammatory markers, even after adjustment 
for multiple other factors.84 With regard to specific anxiety 
disorders, post-traumatic stress disorder (PTSD) has been 
associated with abnormal levels of inflammatory markers 
(eg, IL-1, IL-6, TNF-α, and CRP) in both noncardiac and 
post-MI patients.85,86 In addition, women with diabetes who 
have phobic anxiety have higher levels of inflammatory 
cytokines,87 and generalized anxiety disorder is associated 
with elevated levels of CRP among patients with cardiac 
disease.88
Heart rate variability
Heart rate variability (HRV), a measure of the beat-to-beat 
variability of the heart, involves a complex interplay between 
the sympathetic and parasympathetic nervous systems and 
their impact on the cardiac pacemaker. Decreased HRV 
in post-MI patients has been consistently associated with 
mortality,89 thought to be due in part to elevated risk of 
arrhythmia.90 Several studies have found clinical depression 
to be associated with diminished HRV ,91 including studies 
of depressed cardiac patients,92,93 and given the relative risk 
of arrhythmic events among post-MI patients, depression 
may substantially increase risk of cardiac arrhythmic events 
in this vulnerable population. Likewise, anxiety has been 
associated with decreased HRV94 and both depression and 
anxiety in patients with implantable defibrillators has been 
linked to low HRV .95
Elevated catecholamines
Hyperactivity of the sympathetic nervous system leads to 
increased release of catecholamines in the periphery. This in 
turn leads to vasoconstriction, blood pressure elevation, plate-
let activation, and arrhythmia, all of which can have detrimen-
tal effects on cardiovascular stability. Depression is associated 
with sympathetic nervous system dysregulation,96,97 and, 
similarly, acute anxiety and chronic worry lead to sympathetic 
nervous system hyperactivity and autonomic dysregula-
tion,98–100 providing another potential causative link between 
these disorders and adverse cardiac events.
Endothelial dysfunction
The endothelium is the critical, active layer of tissue 
between circulating blood and the vasculature and is a key 
  regulator of vascular homeostasis. Endothelial dysfunction 
has a substantial impact on cardiovascular health. Indeed, 
  endothelial dysfunction in patients with cardiovascular illness 
has been independently associated with increased rates of car-
diac mortality.101–103 It is increasingly understood that depres-
sion is associated with abnormal function of the endothelium, 
with depressed patients having more abnormalities on 
specialized testing of the endothelium than patients who are 
nondepressed, independent of other factors.104,105 Endothelial 
dysfunction also has been reported in patients with elevated 
levels of anxiety, particularly in the elderly.106–108 Abnormal 
vascular function in the setting of depression or anxiety 
certainly could lead to adverse cardiovascular physiology 
and outcomes.
Behavioral effects
In addition to these physiologic effects, depression is associated 
with poor secondary prevention among patients who have had 
an acute ischemic event. Patients with post-MI depression, 
compared to MI patients who are not depressed, are less likely 
to follow a low fat diet, reduce their cholesterol, exercise, quit 
smoking, or reduce stress in their lives, all of which increase 
their risk for a recurrent cardiac event.109,110 In fact, in the 
large Heart and Soul study111 of patients with depression and 
coronary artery disease, an association between depressive 
symptoms and adverse cardiovascular events was largely 
explained by behavioral factors, especially physical inactivity. 
Patients suffering from anxiety or emotional distress following 
MI also have been found to have difficulty adhering to risk-
reducing behaviors such as easing stress, increasing socializa-
tion, improving diet, and ceasing to smoke.61,112 Finally, patients 
with depression or anxiety may be less likely to attend113,114 
or complete115,116 cardiac rehabilitation programs where both 
their secondary prevention behaviors and their psychiatric 
symptoms could be addressed.
In sum, depression and anxiety have myriad effects on car-
diovascular physiology via a variety of mechanisms and these 
effects likely play a role in the increased incidence of ischemic 
events in patients with these symptoms. Furthermore, the effects 
of depression and anxiety on health-promoting behavior clearly 
play a role in these patients’ poor cardiac outcomes.
Treatments for depression and 
anxiety in cardiac patients
Antidepressants
Antidepressants can be used to treat patients with depres-
sion and patients with formal anxiety disorders, such as Neuropsychiatric Disease and Treatment 2010:6 130
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generalized anxiety disorder, panic disorder, or post-traumatic 
stress disorder. In general, the older tricyclic antidepressants 
(eg, amitriptyline, nortriptyline) should be avoided in 
patients with cardiac illness. First, these agents have 
adverse cardiovascular side effects in this population 
including orthostatic hypotension as well as tachycardia 
due to anticholinergic effects. Furthermore, these agents 
can lengthen cardiac intervals (eg, QRS and QTc) and 
can be proarrhythmic in a subset of the population.117 In 
  epidemiologic studies, prescription of tricyclic antidepressants 
has been associated with increased rates of subsequent MI 
compared to patients receiving selective serotonin reuptake 
inhibitors (SSRIs) or no treatment.118
In contrast, SSRIs appear to be safe and effective in cardiac 
populations. These agents can be used to treat depression and 
formal anxiety disorders (eg, generalized anxiety disorder, 
panic disorder) in cardiac patients. Though SSRIs can be 
associated with increased anxiety, insomnia, or restlessness 
during the first several days of treatment in some patients, 
these effects are generally mild. They do not commonly 
cause orthostasis, tachycardia, or other adverse cardiovascular 
effects, and are well-tolerated in this population. Small trials 
of SSRIs and other antidepressants have found these agents 
to be safe and to significantly reduce symptoms of depression 
in patients with ischemic heart disease.119,120
A larger study, the Canadian Cardiac Randomized 
  Evaluation of Antidepressant and Psychotherapy Efficacy 
(CREATE) placebo-controlled trial of 284 depressed 
  outpatients with coronary artery disease, found that 
  citalopram was significantly more efficacious than pla-
cebo.28 Citalopram was well-tolerated in this study and 
was not associated with serious adverse events. Further, the 
multicenter SADHART randomized controlled trial of 369 
post-ACS patients with major depressive disorder (MDD) 
found sertraline to be safe, well-tolerated, and efficacious in 
patients who began treatment approximately 1 month post-
ACS.10 Furthermore, a post hoc analysis of the Enhancing 
Recovery in Coronary Heart Disease Patients (ENRICHD) 
trial (a trial of cognitive behavioral therapy (CBT) for post-
MI depression that had some patients taking antidepressants 
in both the experimental and control groups) found that 
patients receiving SSRIs had an over 40% reduction in the 
risk of cardiac mortality and reinfarction over a mean 29 
month follow-up, compared to those not taking SSRIs.121 
One potential mechanism by which SSRIs may reduce 
cardiac events may involve reduction of platelet activity, 
as treatment of depressed patients with SSRIs leads to 
decreased markers of platelet hyperactivity.65,122,123
Regarding other antidepressant agents, mirtazapine was 
studied in the randomized controlled Myocardial INfarction 
and Depression – Intervention Trial (MIND-IT) for patients 
with post-MI depression. The authors found that mirtazapine 
was safe, well-tolerated, and more efficacious than placebo 
over the 24 week trial.124 However, treatment with mirtazapine 
did not appear to impact cardiovascular outcomes,125 and 
some side effects of this agent (eg, weight gain, increased 
lipids) may relegate it to second-line status on patients with a 
history of myocardial ischemia. Finally, there is less evidence 
for the use of mirtazapine for anxiety disorders compared 
to the SSRIs.
Bupropion, while relatively unstudied for depression in 
patients with cardiac illness, has been studied in post-MI 
patients as an aid to smoking cessation. These studies found 
this agent to be safe and well-tolerated in this subset of patients 
(though it can cause anxiety, restlessness, or insomnia) and 
it has not been associated with increased rates of serious 
  cardiovascular side effects.126 Therefore bupropion may 
be indicated in depressed cardiac patients who wish to quit 
  smoking. Other antidepressants, such as venlafaxine and 
duloxetine, have not been well-studied in cardiac populations, 
though venlafaxine is known to have dose-dependent increases 
in blood pressure associated with its use.127
In sum, the SSRIs are well-studied agents for depression 
in patients with cardiac disease, are safe and efficacious in 
this population, can also be used for patients with anxiety 
disorders, and may be associated with decreased rates of 
adverse cardiac outcomes. Other antidepressants can be used 
under specific circumstances, though tricyclic antidepressants 
are generally not recommended.
Benzodiazepines
Benzodiazepines are effective in the reduction of acute anxiety 
and are effective in the treatment of some anxiety disorders 
(eg, panic disorder). These agents are rapidly effective and 
are well-used in patients with ongoing or recent myocardial 
ischemia for whom anxiety is leading to elevated heart rate, 
blood pressure, or other physiologic difficulties. These agents 
have several beneficial physiologic effects including acutely 
  lowering catecholamine levels and decreasing coronary 
  vascular resistance.11,128,129 However, there are several caveats 
with the use of these agents: they can be associated with 
increased risk of falls, sedation, respiratory depression, and 
physiologic dependence,130 and they do not treat comorbid 
depressive symptoms. Despite these caveats, these rapidly-act-
ing anxiolytics can be substantially effective among patients 
with ischemic heart disease and ongoing anxiety,131 though Neuropsychiatric Disease and Treatment 2010:6 131
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for patients with depression or formal anxiety disorders, 
  antidepressants are often the treatment of choice.
Psychotherapy
Psychotherapeutic interventions are appealing for cardiac 
patients because of their lack of somatic side effects. In 
  addition, these interventions can be individualized to 
focus on a given patient’s specific difficulties. Specific 
forms of psychotherapy have been studied in cardiac 
patients. The largest trial of psychotherapy in post-MI 
patients, the previously mentioned ENRICHD trial of 
2481 patients,9 found that treatment with CBT significantly 
reduced depressive symptoms and improved quality of life 
among post-MI patients, though it did not (in contrast to 
  antidepressants) improve cardiac outcomes. The CREATE 
trial, in addition to studying citalopram, also utilized an 
evidence-based treatment called interpersonal psychotherapy 
(IPT), but found it did not improve depressive symptoms 
compared to an active control.28 To our knowledge, there 
has not been a psychotherapeutic intervention for anxiety 
in cardiac patients, though CBT has been used to treat a 
wide variety of anxiety disorders in other populations.132 
Finally, a variety of other supportive and psychotherapeutic 
  interventions have been used in patients with cardiovascular 
disease for a variety of conditions and though the studies of 
many of these interventions have been less rigorous than 
those listed above, they appear to improve outcomes.133
Overall, psychotherapy can be effective for cardiac 
patients with depression or anxiety, though it may have 
less efficacy or impact on medical outcomes than treatment 
with antidepressants. A further pragmatic difficulty with 
  psychotherapy is that such therapy, particularly evidence-
based forms of treatment, can be difficult to source, especially 
in areas without nearby academic centers.
Exercise and cardiac rehabilitation
Exercise is an effective antidepressant,134 is associated 
with reduced anxiety,135 and has substantial cardiovascular 
  benefit. A pair of trials of exercise (30 minutes of continuous 
walking/jogging to reach a target heart rate, three times per 
week for 16 weeks) in depressed patients found that regular 
exercise was as effective as sertraline in the treatment 
of depression.134,136 Follow-up results from the first trial, 
six months after the end of the study, found depression 
  improvements among patients in the exercise group to be 
sustained longer than in those receiving antidepressants.137 In 
addition, cardiac rehabilitation programs can provide many 
services that are helpful to cardiac patients with depression, 
from ongoing depression evaluation, to social support, to 
specific interventions for cardiovascular health. Therefore, 
both of these interventions can be tremendously helpful for 
cardiac patients with psychological distress.
However, cardiac patients with depression are less 
likely to exercise than their nondepressed counterparts110 
and, as noted, are less likely to attend and complete cardiac 
  rehabilitation programs.114,116 Anxiety also appears to reduce 
participation in these programs.115 Clinically, we often find 
that improving patients’ depression, anxiety, and distress 
initially with medication or psychotherapy is necessary 
before they are willing and able to participate in exercise or 
cardiac rehabilitation.
Impact of cardiovascular medications  
on mood and anxiety symptoms
Patients with cardiac disease, especially those with a history 
of ischemic events, may be prescribed multiple medications. 
In general, many commonly prescribed agents, including 
aspirin, clopidogrel, warfarin, angiotensin-converting enzyme 
inhibitors, and nitrates are not associated with substantial 
psychiatric effects.138 Though low cholesterol has been 
associated with increased rates of depression, aggression, and 
suicidality in some trials,139–142 this link has also been refuted 
in several studies. Furthermore, lowering serum cholesterol 
does not appear to increase the risk of depression or suicidal 
behavior143 and studies of lipid-lowering agents such as 
HMG-CoA reductase inhibitors (‘statins’) have not found 
any association between these agents and mood symptoms, 
aggression, or changes in cognition.144,145
Finally, the association between beta-blockers and 
  depression has long been controversial. A number of case 
reports and several small studies (that sometimes did not 
control for some important covariables) found associations 
between propranolol and the onset of depression,146,147 
  however, a larger prospective controlled study and 
  comprehensive review of the literature on propranolol found 
no association between this agent and depression.148,149 When 
expanded to include other beta-blockers, the majority of 
studies and reviews, including a large 2002 meta-analysis,150 
found no association with depression, though there is some 
association between beta-blockers and fatigue. On the 
other hand, beta-blockers, specifically propranolol, have 
been found to be effective in the treatment of anxiety and 
  aggression.151,152 In sum, the relationship between propranolol 
and depression is equivocal. There is probably no association 
between beta-blockers and depression for the other agents in 
this class, though idiosyncratic reactions are always possible. Neuropsychiatric Disease and Treatment 2010:6 132
Huffman et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
In contrast, propranolol can be used as a therapeutic agent 
for cardiac patients with anxiety or aggression.
Conclusion
Depression and anxiety among patients with acute myocardial 
ischemia are highly prevalent and independently associated 
with adverse cardiovascular outcomes, including mortality. At 
this point, there is little doubt that addressing these conditions 
is critical in cardiac patients, but there remain a number of 
research and clinical steps to bridge the gap between this 
knowledge and patients receiving optimal care.
With respect to future research, it will be important to 
learn more about the combined effects of depression and 
anxiety on cardiac outcomes. Another important goal is 
the identification of subsets of cardiac patients for whom 
early and aggressive treatment of depression and anxiety is 
  particularly critical. In addition, a better understanding of the 
mechanisms by which these psychiatric symptoms impair 
cardiovascular health may allow the development of mecha-
nism-specific treatments. Finally, large prospective studies, if 
feasible, of existing treatments of depression and anxiety (eg, 
SSRIs) to determine whether cardiac outcomes improve as a 
result of their use would provide highly valuable information 
about the medical impact of these treatments.
Clinically, it is vital to find ways to help front-line 
  practitioners to systematically identify depression and 
anxiety among their patients with cardiovascular disease. 
Likewise, it is necessary to develop infrastructure such that 
identified patients receive basic, but critical, treatments for 
these disorders. One future step that could combine clinical 
care and research is further investigation of care management 
models. These models of assessment and treatment utilize a 
care manager to efficiently identify patients with depression 
and anxiety. The care manager then coordinates treatment 
between patient, primary care physician, and consulting 
psychiatrist in a longitudinal manner. Such models have been 
used in outpatient medical settings and have been found to 
significantly improve depression and anxiety outcomes in a 
cost-effective manner.153–156 Most recently, such a model led to 
improved outcomes in depressed patients undergoing cardiac 
surgery.157 Patients with a history of acute cardiovascular 
disease, such as ACS, represent a population who may most 
benefit from care management programs, given the strong 
link between depression/anxiety and medical outcomes.
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